Availability of Trulicity®

HPS Pharmacies wish to advise that Eli Lilly is experiencing a supply interruption for Trulicity® as follows:

Trulicity® Pen
Dulaglutide (rch) 1.5 mg/0.5 mL
ARTG 217965 

This supply interruption is due to an unexpected increase in demand. Normal supplies are expected to return by end-August 2022. An internationally registered brand of dulaglutide (rch) 1.5 mg/0.5 mL pens has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Eli Lilly on 1800 454 559 or your pharmacist at HPS Pharmacies.

Availability of Ozempic®

HPS Pharmacies wish to advise that Novo Nordisk is continuing to experience a supply interruption for Ozempic® as follows:

Ozempic® 0.25/0.5mg Pen
Semaglutide 1.34mg/mL
ARTG 308324

Ozempic® 1mg Pen
Semaglutide 1.34mg/mL
ARTG 315107

Supplies of Ozempic® are currently limited due to an unexpected increase in demand. Normal supplies are expected to return by end-December 2022. An internationally registered brand of semaglutide 0.25/0.5mg pens and semaglutide 1mg pens has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.

A statement is available on the Therapeutic Goods Administration (TGA) website reminding health professionals to prioritise the supply of semaglutide for patients with type 2 diabetes.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Novo Nordisk on 1800 668 626 or your pharmacist at HPS Pharmacies.

Availability of Pulmicort® Turbuhaler®

HPS Pharmacies wish to advise that AstraZeneca is experiencing a supply interruption for Pulmicort® Turbuhaler® as follows:

Pulmicort® Turbuhaler®
Budesonide 200 microgram/ actuation
ARTG 10065

Normal supplies of Pulmicort® Turbuhaler® 200mcg are expected to resume by end-August 2022.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact AstraZeneca on 1800 805 342 or your pharmacist at HPS Pharmacies.

Packaging alert for Xylocaine® 2% with Adrenaline

HPS Pharmacies wish to give notice of an alert for Xylocaine® 2% with Adrenaline as follows:

Xylocaine® 2% with Adrenaline Vial, 20mL
Lidocaine (lignocaine) 5mg/mL + adrenaline (epinephrine) 5microgram/mL  

This alert only relates to the internationally-registered product supplied under Section 19A of the Therapeutic Goods Act 1989 while the Australian-registered product is unavailable.

HPS Pharmacies has been advised that the Canadian supplier of the S19A alternative has incorrectly shipped a product containing preservative instead of the preservative-free product. The administration of Xylocaine® with preservative may cause patient harm, particularly when the intrathecal or epidural routes are used.

The only batch affected by this issue is batch #9949864.

HPS Pharmacies can confirm that we have not received or supplied to our clients any product from this batch. The similar packaging of the two products is shown below for informational purposes.

Xylocaine® 2% with Adrenaline with preservative:

Xylocaine® 2% with Adrenaline without preservative:

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please refer to the Safer Care Victoria notice (available here) or contact your pharmacist at HPS Pharmacies.

Availability of Cetrotide®

HPS Pharmacies wish to advise that Merck Healthcare is anticipating a supply interruption for Cetrotide® as follows:

Cetrotide® Injection
Cetrorelix (as acetate) 250 microgram
ARTG 74888

A shortage of Cetrotide® is expected to occur at the end of August 2022 and last until the end of October 2022. This is due to technical problems at the main manufacturing site which has led to the reduced and delayed supply of Cetrotide®. The quality of the manufactured and released product batches is not affected by these technical issues.

HPS Pharmacies currently has access to a supply of Cetrotide® that has been restricted according to our historical usage. When supplies are exhausted, Merck Healthcare advises that alternative GnRH antagonists may be considered. Two brands of ganirelix are currently available, Orgalutran® and Ganirelix SUN.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Merck Healthcare on 1800 257 348 or your pharmacist at HPS Pharmacies.

Availability of Vecure®

HPS Pharmacies wish to advise that Alphapharm is experiencing a supply interruption for Vecure® as follows:

Vecure® Vials
Vecuronium bromide 10mg
ARTG 165350

Normal supplies are expected to resume in early August 2022.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Alphapharm on 1800 274 276 or your pharmacist at HPS Pharmacies.

Availability of Morphine Juno 50mg Ampoules

HPS Pharmacies wish to advise that Juno Pharmaceuticals is experiencing a supply interruption for Morphine Juno ampoules as follows:

Morphine Juno Ampoules
Morphine hydrochloride trihydrate 50 mg/5 mL
ARTG 224251

Resupply is expected by 11 August 2022.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.

Availability of BenPen™

HPS Pharmacies wish to give notice that Seqirus is experiencing a supply interruption for BenPen as follows:

BenPen Vials
Benzylpenicillin (as sodium) 1.2g
ARTG 10326

BenPen Vials
Benzylpenicillin (as sodium) 3g
ARTG 10327

Normal supplies of BenPen 1.2g and 3g vials are expected to resume by mid-late August 2022. An internationally registered brand of benzylpenicillin 1.2g vials has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.

Some wholesalers may also experience short-term supply interruptions for BenPen 600mg during this time. However, this product may be considered as a substitute where appropriate and available.

If a suitable presentation of benzylpenicillin is not available, an Infectious Disease specialist should be consulted for advice.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Seqirus on 1800 642 865, or your pharmacist at HPS Pharmacies.

Availability of Chlorsig® Ointment

HPS Pharmacies wish to give notice that Aspen is experiencing a supply interruption for Chlorsig® Ointment as follows:

Chlorsing® 1% Ointment
Chloramphenicol 10 mg/g
ARTG 19662

Normal supplies are expected to resume by end-July 2022.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Aspen on 1300 659 646, or your pharmacist at HPS Pharmacies.

Availability Of Metronidazole Tablets

HPS Pharmacies wish to advise that there is currently a supply interruption for metronidazole tablets as follows:

Product ARTG Estimated return date
Metrogyl® 200mg 17654 Late July to early August 2022
Metrogyl® 400mg 17655 Late July 2022
Flagyl® 200mg 160171 Discontinued
Flagyl® 400mg 160174 Late August 2022
Metronide® 200mg 160173 Discontinued
Metronide® 400mg 160175 Discontinued

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.